Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV
NCT07871552 is a phase 2 interventional trial sponsored by The University of Texas Health Science Center, Houston. As of 21 Nov 2026, it is not yet recruiting. It studies Continue SoC ART, Switch from an ART regimen containing lamivudine or emtricitabine + tenofovir alafenamide or tenofovir disoproxil fumarate to DOR/ISL and Switch from an nucleoside reverse transcriptase inhibitor-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL in Epigenetic Aging. The registry lists an enrollment of 60 participants at 2 sites in 1 country. The registry lists a start date of 30 Oct 2026 and a primary completion date of 15 Apr 2028. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT07871552 |
| Status | Not yet recruiting |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | The University of Texas Health Science Center, Houston |
| Enrollment | 60 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Epigenetic Aging |
| Drugs | Continue SoC ART, Switch from an ART regimen containing lamivudine or emtricitabine + tenofovir alafenamide or tenofovir disoproxil fumarate to DOR/ISL and Switch from an nucleoside reverse transcriptase inhibitor-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL |
| Start | 30 Oct 2026 |
| Primary completion | 15 Apr 2028 |
| Study completion | 15 Oct 2028 |
| Last update posted | 23 Oct 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Jordan E Lake, MD, MSc
The University of Texas Health Science Center, Houston
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Colorado Anschutz Medical Center
Aurora
- the University of Texas Health Science Center at Houston
Houston
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT07871552
Each answer restates registry values shown on this page.
What is NCT07871552?
NCT07871552 is a phase 2 interventional trial sponsored by The University of Texas Health Science Center, Houston. It studies Continue SoC ART, Switch from an ART regimen containing lamivudine or emtricitabine + tenofovir alafenamide or tenofovir disoproxil fumarate to DOR/ISL and Switch from an nucleoside reverse transcriptase inhibitor-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL in Epigenetic Aging.
Is NCT07871552 recruiting?
As of 21 Nov 2026, it is not yet recruiting.
Who leads NCT07871552?
The registry names Jordan E Lake, MD, MSc (principal investigator, The University of Texas Health Science Center, Houston) as the overall official.
Where does NCT07871552 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT07871552 study?
The registered drug and biological interventions are Continue SoC ART, Switch from an ART regimen containing lamivudine or emtricitabine + tenofovir alafenamide or tenofovir disoproxil fumarate to DOR/ISL and Switch from an nucleoside reverse transcriptase inhibitor-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL.
When is NCT07871552 expected to complete?
The registry lists a primary completion date of 15 Apr 2028 and a study completion date of 15 Oct 2028. The sponsor last updated the record on 23 Oct 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.